Cerebral Venous Thrombosis Follow-up

  • Author: W Alvin McElveen, MD; Chief Editor: Helmi L Lutsep, MD   more...
 
Updated: Nov 14, 2011
 

Prognosis

Smith compared outcomes of patients treated with heparin and local infusion of urokinase with those of patients who received no treatment.[29] Twelve patients received treatment and 21 patients received no treatment. Results are tabulated below.

Table. Patients With Cerebral Venous Thrombosis Treated With Heparin and Local Infusion of Urokinase vs Nontreated Group (Open Table in a new window)

Treated Group, % (n = 12)Nontreated Group, % (n = 21)
Full recovery62.529
Mild disability12.513
Severe disability12.59.6
Fatal outcome12.548
 
Contributor Information and Disclosures
Author

W Alvin McElveen, MD  Director, Stroke Unit, Lakewood Ranch Medical Center; Neurologist, Manatee Memorial Hospital

W Alvin McElveen, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Neuroimaging, American Stroke Association, and Southern Clinical Neurological Society

Disclosure: Nothing to disclose.

Coauthor(s)

Ralph F Gonzalez, MD  Private Practice, Bradenton Neurology, Inc; Consulting Staff, Department of Neurology, Blake Hospital, Lakewood Ranch Medical Center, Manatee Memorial Hospital

Ralph F Gonzalez, MD is a member of the following medical societies: American Academy of Neurology and Florida Medical Association

Disclosure: Nothing to disclose.

Andrew P Keegan, MD  Private Practice, Bradenton Neurology, Inc; Consulting Staff, Department of Neurology, Manatee Memorial Hospital, Lakewood Ranch Medical Center, Blake Medical Center

Andrew P Keegan, MD is a member of the following medical societies: American Academy of Neurology and American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Norman C Reynolds Jr, MD  Neurologist, Veterans Affairs Medical Center of Milwaukee; Clinical Professor, Medical College of Wisconsin

Norman C Reynolds Jr, MD is a member of the following medical societies: American Academy of Neurology, Association of Military Surgeons of the US, Movement Disorders Society, Sigma Xi, and Society for Neuroscience

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Howard S Kirshner, MD  Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center

Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Helmi L Lutsep, MD  Professor, Department of Neurology, Oregon Health and Science University School of Medicine; Associate Director, Oregon Stroke Center

Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association

Disclosure: Co-Axia Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Concentric Medical Consulting fee Review panel membership

References

  1. Towbin A. The syndrome of latent cerebral venous thrombosis: its frequency and relation to age and congestive heart failure. Stroke. May-Jun 1973;4(3):419-30. [Medline].

  2. Daif A, Awada A, al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke. Jul 1995;26(7):1193-5. [Medline].

  3. Ferro JM, Lopes MG, Rosas MJ, et al. Long-Term Prognosis of Cerebral Vein and Dural Sinus Thrombosis. results of the venoport study. Cerebrovasc Dis. 2002;13(4):272-8. [Medline].

  4. Buccino G, Scoditti U, Patteri I, et al. Neurological and cognitive long-term outcome in patients with cerebral venous sinus thrombosis. Acta Neurol Scand. May 2003;107(5):330-5. [Medline].

  5. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. Feb 1992;10(1):87-111. [Medline].

  6. Galarza M, Gazzeri R. Cerebral venous sinus thrombosis associated with oral contraceptives: the case for neurosurgery. Neurosurg Focus. Nov 2009;27(5):E5. [Medline].

  7. Flores-Barragan JM, Hernandez-Gonzalez A, Gallardo-Alcaniz MJ, Del Real-Francia MA, Vaamonde-Gamo J. [Clinical and therapeutic heterogeneity of cerebral venous thrombosis: a description of a series of 20 cases.]. Rev Neurol. Dec 1-15 2009;49(11):573-6. [Medline].

  8. Wasay M, Kojan S, Dai AI, Bobustuc G, Sheikh Z. Headache in Cerebral Venous Thrombosis: incidence, pattern and location in 200 consecutive patients. J Headache Pain. Apr 2010;11(2):137-9. [Medline].

  9. Oppenheim C, Domigo V, Gauvrit JY, et al. Subarachnoid hemorrhage as the initial presentation of dural sinus thrombosis. AJNR Am J Neuroradiol. Mar 2005;26(3):614-7. [Medline].

  10. Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. May 13 2003;60(9):1418-24. [Medline].

  11. Ennaifer R, Moussa A, Mouelhi L, et al. Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis. Acta Gastroenterol Belg. Jul-Sep 2009;72(3):350-3. [Medline].

  12. Cesarman-Maus G, Cantú-Brito C, Barinagarrementeria F, Villa R, Reyes E, Sanchez-Guerrero J. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke. Feb 2011;42(2):501-3. [Medline].

  13. Schievink WI, Maya MM. Cerebral venous thrombosis in spontaneous intracranial hypotension. Headache. Nov-Dec 2008;48(10):1511-9. [Medline]. [Full Text].

  14. Canhão P, Batista P, Falcão F. Lumbar puncture and dural sinus thrombosis--a causal or casual association?. Cerebrovasc Dis. 2005;19(1):53-6. [Medline].

  15. Tardy B, Tardy-Poncet B, Viallon A, et al. D-dimer levels in patients with suspected acute cerebral venous thrombosis. Am J Med. Aug 15 2002;113(3):238-41. [Medline].

  16. Lalive PH, de Moerloose P, Lovblad K, et al. Is measurement of D-dimer useful in the diagnosis of cerebral venous thrombosis?. Neurology. Oct 28 2003;61(8):1057-60. [Medline].

  17. Kosinski CM, Mull M, Schwarz M, et al. Do normal D-dimer levels reliably exclude cerebral sinus thrombosis?. Stroke. Dec 2004;35(12):2820-5. [Medline].

  18. Adams WM, Laitt RD, Beards SC, et al. Use of single-slice thick slab phase-contrast angiography for the diagnosis of dural venous sinus thrombosis. Eur Radiol. 1999;9(8):1614-9. [Medline].

  19. Ayanzen RH, Bird CR, Keller PJ, et al. Cerebral MR venography: normal anatomy and potential diagnostic pitfalls. AJNR Am J Neuroradiol. Jan 2000;21(1):74-8. [Medline].

  20. Mas JL, Meder JF, Meary E, Bousser MG. Magnetic resonance imaging in lateral sinus hypoplasia and thrombosis. Stroke. Sep 1990;21(9):1350-6. [Medline].

  21. Ozsvath RR, Casey SO, Lustrin ES, et al. Cerebral venography: comparison of CT and MR projection venography. AJR Am J Roentgenol. Dec 1997;169(6):1699-707. [Medline].

  22. Medel R, Monteith SJ, Crowley RW, Dumont AS. A review of therapeutic strategies for the management of cerebral venous sinus thrombosis. Neurosurg Focus. Nov 2009;27(5):E6. [Medline].

  23. Bentley JN, Figueroa RE, Vender JR. From presentation to follow-up: diagnosis and treatment of cerebral venous thrombosis. Neurosurg Focus. Nov 2009;27(5):E4. [Medline].

  24. de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third- generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet. May 9 1998;351(9113):1404. [Medline].

  25. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet. Sep 7 1991;338(8767):597-600. [Medline].

  26. Rahman M, Velat GJ, Hoh BL, Mocco J. Direct thrombolysis for cerebral venous sinus thrombosis. Neurosurg Focus. Nov 2009;27(5):E7. [Medline].

  27. Ekseth K, Bostrom S, Vegfors M. Reversibility of severe sagittal sinus thrombosis with open surgical thrombectomy combined with local infusion of tissue plasminogen activator: technical case report. Neurosurgery. Oct 1998;43(4):960-5. [Medline].

  28. Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, Cucchiara B. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke. Oct 2011;42(10):2825-31. [Medline].

  29. Smith AG, Cornblath WT, Deveikis JP. Local thrombolytic therapy in deep cerebral venous thrombosis. Neurology. Jun 1997;48(6):1613-9. [Medline].

  30. Alonso-Canovas A, Masjuan J, Gonzalez-Valcarcel J, et al. [Cerebral venous thrombosis: when etiology makes the difference.]. Neurologia. Sep 2009;24(7):439-45. [Medline].

  31. Benamer HT, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolyic therapy?. J Neurol Neurosurg Psychiatry. Oct 2000;69(4):427-30. [Medline].

  32. Cipri S, Gangemi A, Campolo C, et al. High-dose heparin plus warfarin administration in non-traumatic dural sinuses thrombosis. A clinical and neuroradiological study. J Neurosurg Sci. Mar 1998;42(1):23-32. [Medline].

  33. D'Alise MD, Fichtel F, Horowitz M. Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion. Surg Neurol. Apr 1998;49(4):430-5. [Medline].

  34. Davis KR, Kistler JP, Buonanno FS. Clinical neuroimaging approaches to cerebrovascular diseases. Neurol Clin. Nov 1984;2(4):655-65. [Medline].

  35. Gold Standard Multimedia. Urokinase, Altevase, Streptokinase, Heparin, Warfarin. Clinical Pharmacology. 2000;Available at:http://cp.gsm.com/. [Full Text].

  36. Gomez CR, Misra VK, Terry JB, et al. Emergency endovascular treatment of cerebral sinus thrombosis with a rheolytic catheter device. J Neuroimaging. Jul 2000;10(3):177-80. [Medline].

  37. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. Jul 15 2003;109 Suppl 1:S9-15. [Medline].

  38. Jacobs K, Moulin T, Bogousslavsky J, et al. The stroke syndrome of cortical vein thrombosis. Neurology. Aug 1996;47(2):376-82. [Medline].

  39. Leys D, Cordonnier C. Cerebral venous thrombosis: Update on clinical manifestations, diagnosis and management. Ann Indian Acad Neurol. 2008;11:79-87. [Full Text].

  40. Meyer-Lindenberg A, Quenzel EM, Bierhoff E, et al. Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia. Eur Neurol. 1997;37(3):191-2. [Medline].

  41. Zweifler RM. Management of acute stroke. South Med J. Apr 2003;96(4):380-5. [Medline].

 
Previous
Next
 
Case 1: Left lateral sinus thrombosis demonstrated on MR venography. This 42-year-old woman presented with sudden onset of headache. Physical examination revealed no neurological abnormalities.
Case 1: One week after treatment with heparin, the MR venogram displayed increased flow in the left lateral sinus consistent with early recanalization of the sinus; headache had resolved at this point.
Magnetic resonance venogram - axial view; A = lateral (transverse) sinus; B = sigmoid sinus; C = confluence of sinuses; and D = superior sagittal sinus.
Magnetic resonance venogram - sagittal view; A = lateral (transverse) sinus; C = confluence of sinuses; D = superior sagittal sinus; and E = straight sinus.
Case 2: CT scan demonstrates a left posterior temporal hematoma in a 38-year-old woman on oral contraceptives (the only identified risk factor).
Case 2: Contrast-enhanced MRI showing lack of filling of left transverse sinus.
Case 2: Axial view of MR venogram demonstrating lack of flow in transverse sinus.
Case 2: Coronal view of MR venogram demonstrating lack of flow in the left transverse and sigmoid sinuses.
Table. Patients With Cerebral Venous Thrombosis Treated With Heparin and Local Infusion of Urokinase vs Nontreated Group
Treated Group, % (n = 12)Nontreated Group, % (n = 21)
Full recovery62.529
Mild disability12.513
Severe disability12.59.6
Fatal outcome12.548
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.